PT - JOURNAL ARTICLE AU - H. Majiya AU - M. Aliyu-Paiko AU - V.T. Balogu AU - D.A. Musa AU - I.M. Salihu AU - A.A. Kawu AU - Y.I. Bashir AU - R.A. Sani AU - J. Baba AU - A.T. Muhammad AU - F.L. Jibril AU - E. Bala AU - N.G. Obaje AU - B.Y. Aliyu AU - R.G. Muhammad AU - H. Mohammed AU - N.U. Gimba AU - A. Uthman AU - H.M. Liman AU - A.A. Sule AU - K.J. Joseph AU - M.M. Makusidi AU - M.D. Isah AU - I. Abdullahi AU - U. Ndagi AU - B. Waziri AU - C.I. Bisallah AU - N.J. Dadi-Mamud AU - K. Ibrahim AU - A.K. Adamu TI - Seroprevalence of COVID-19 in Niger State AID - 10.1101/2020.08.04.20168112 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.04.20168112 4099 - http://medrxiv.org/content/early/2020/08/05/2020.08.04.20168112.short 4100 - http://medrxiv.org/content/early/2020/08/05/2020.08.04.20168112.full AB - Coronavirus Disease 2019 (COVID-19) Pandemic is ongoing, and to know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the COVID-19 seroprevalence, patterns, dynamics, and risk factors in the state. A cross sectional study design and clustered-stratified-Random sampling strategy were used. COVID-19 IgG and IgM Rapid Test Kits (Colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to SARS-CoV-2 in the blood of sampled participants across Niger State as from 26th June 2020 to 30th June 2020. The test kits were validated using the blood samples of some of the NCDC confirmed positive and negative COVID-19 cases in the State. COVID-19 IgG and IgM Test results were entered into the EPIINFO questionnaire administered simultaneously with each test. EPIINFO was then used for both the descriptive and inferential statistical analyses of the data generated. The seroprevalence of COVID-19 in Niger State was found to be 25.41% and 2.16% for the positive IgG and IgM respectively. Seroprevalence among age groups, gender and by occupation varied widely. A seroprevalence of 37.21% was recorded among health care workers in Niger State. Among age groups, COVID-19 seroprevalence was found to be in order of 30-41 years (33.33%) > 42-53 years (32.42%) > 54-65 years (30%) > 66 years and above (25%) > 6-17 years (19.20%) > 18-29 years (17.65%) > 5 years and below (6.66%). A seroprevalence of 27.18% was recorded for males and 23.17% for females in the state. COVID-19 asymptomatic rate in the state was found to be 46.81%. The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers and those that have had contact with person (s) that travelled out of Nigeria in the last six (6) months are twice (2 times) at risk of being infected with the virus. More than half (54.59%) of the participants in this study did not practice social distancing at any time since the pandemic started. Discussions about knowledge, practice and attitude of the participants are included. The observed Niger State COVID-19 seroprevalence means that the herd immunity for COVID-19 is yet to be achieved and the population is still susceptible for more infection and transmission of the virus. If the prevalence stays as reported here, the population will definitely need COVID-19 vaccines when they become available. Niger State should fully enforce the use of face/nose masks and observation of social/physical distancing in gatherings including religious gatherings in order to stop or slow the spread of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Ibrahim Badamasi Babangida University, Lapai, Niger State, Nigeria.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee, Niger Sate Ministry of Health, Minna, NigeriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available